Micronized progesterone: A new therapeutic option

International Journal of Fertility and Women's Medicine

Volumn 44, Issue 2, 1999, Pages 67-73

  Langer, Robert D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardioprotection; HRT; Pharmacokinetics; Progesterone; Progestogens; Side effects

Indexed keywords

MEDROXYPROGESTERONE ACETATE; NORGESTREL; PROGESTERONE;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG UPTAKE; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTESTINE ABSORPTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; METRORRHAGIA; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; SECONDARY AMENORRHEA; SUSTAINED RELEASE PREPARATION;

DOSAGE FORMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; PREMENOPAUSE; PROGESTERONE; THERAPEUTIC EQUIVALENCY;

EID: 0032959053     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Shangold MM, Tomai TP, Cook JD, et al: Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril 56:1040-1047, 1991.
2. Pouly JL, Bassil S, Frydman R, et al: Luteal support after in-vitro fertilization. Crinone 8%, a sustained release vaginal progesterone gel, versus Ultrogestan, an oral micronized progesterone. Hum Reprod 11:2085-2089, 1996.
3. Miles RA, Paulson RJ, Lobo RA, et al: Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 62:485-490, 1994.
4. NCHS: Vital Statistics of the United States. 1990.
5. NCHS: Vital Statistics of the United States; Tables 1-9, 1988.
6. National Center for Health Statistics: Health, United States, 1998. Hyattsville, Maryland, 1998, Tables 38 & 40.
7. NCHS: Current Estimates from the NHIS, Series 10, #181, Table 58. 1990.
8. Kannel WB, Hjortland MC, MCNamera, et al: Menopause and the risk of cardiovascular disease: the Framingham study. Ann Intern Med 85:447-452, 1976.
9. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037, 1992.
10. Menopausal estrogens and cardiovascular disease. Obstet Gynecol 2:255-265, 1990.
11. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? Br Med J (Clin Res) 308(6939):1268-1269, 1994.
12. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335(7): 453-461, 1996.
13. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20:47-63, 1991.
14. Bush TL, Fried LP, Barrett-Connor E: Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem 34(8B):B60-70, 1988.
15. Pike MC, Henderson BF, Mack TM, et al: Stroke prevention and oestrogen replacement. Lancet 2(8670):1034-1035, Oct 28, 1989.
16. Barrett-Connor E: Postmenopausal estrogen and prevention bias. Ann Intern Med 115:455-456, 1991.
17. The PEPI Investigators: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273(3):199-208, 1995.
18. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998.
19. Anderson KM, Odell PM, Wilson PWF, Kannel WB: Cardiovascular risk profiles. Am Heart J 121:293-298, 1991.
20. Adams MR, Kaplan JR, Manuck SB, et al: Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10:1051-1057, 1990.
21. Adams MR, Register TC, Golden DL, et al: Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 17: 217-221, 1997.